High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
AbbVie's blockbuster drugs are surging while a major acquisition looms, but a trailing P/E of 71 and one model pricing the stock nearly $50 below current levels raises a real question about whether the rally has room left to run.
Merck raised its 2026 sales outlook as pipeline gains, new launches and post-KEYTRUDA plans took focus despite acquisition-driven losses.
MSD is currently evaluating tulisokibart in six different indications following the drug’s discontinuation in SSc-ILD.
Merck & Co., Inc. (NYSE:MRK) reported second-quarter revenue of $16.6 billion, up 5% from a year earlier, driven by oncology, animal health and contributions from newer product launches. Revenue increased 4% excluding foreign exchange, according to Chief Financial Officer Caroline Litchfield. T
Keytruda made Merck an oncology powerhouse, but as the patent cliff looms, its business development leader outlines what’s next.
Moby summary of Merck & Co., Inc.'s Q2 2026 earnings call
Merck raises full-year guidance on robust KEYTRUDA and new product momentum, while navigating acquisition-related EPS impact and pipeline setbacks.
Gilead Sciences posts higher revenue as its market-leading HIV drug portfolio continues to drive growth.
Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index down 0.7% and th
Merck's (MRK) "HIV pipeline" is brewing in the background, as weekly treatment are interesting and s
By Michael Erman and Christy Santhosh Aug 4 (Reuters) - Merck reported higher-than-expected second-quarter sales on Tuesday and raised its full-year revenue forecast on the strength of its top-selling
Although the revenue and EPS for Merck (MRK) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Merck (NYSE:MRK) shares moved higher in pre-market trading after the pharmaceutical company reported second-quarter 2026 results that exceeded Wall Street expectations and raised its full-year revenue guidance. Although Merck reduced its adjusted earnings outlook to reflect acquisition-related charges, investors welcomed the stronger-than-expected quarterly performance and improved sales forecast.
Global pharmaceutical company Merck (NYSE:MRK) announced better-than-expected revenue in Q2 CY2026, with sales up 5.1% year on year to $16.61 billion. The company expects the full year’s revenue to be around $66.8 billion, close to analysts’ estimates. Its non-GAAP loss of $0.13 per share was 49.5% above analysts’ consensus estimates.
Stock futures pointed to a strong opening Tuesday, a day after the Dow Jones Industrial Average set a new closing record, as Palantir led tech shares higher and oil prices fell further.
Merck's new injectable version of Keytruda walloped sales expectations Tuesday, packing a $200 million-plus punch vs. Wall Street's forecasts.
Today Earnings (a.m.): Merck, Pfizer, McDonald's, Caterpillar, Spotify, Apollo, TPG, Marathon Petroleum, Archer-Daniels-Midland, DuPont, Kimberly-Clark Earnings (p.m.): SpaceX, Advanced Micro Devices, ...
SCHD charges just 0.06% per year, but taxable investors who lived through the March reconstitution discovered a second bill arriving in a very different form. Here is what the expense ratio line was never designed to show you.
Agilent Technologies Inc. (NYSE:A) just extended its diagnostics franchise into one of oncology’s toughest corners. On July 23, the company said European regulators had certified its PD-L1 IHC 22C3 pharmDx test, Code SK006, as a companion diagnostic for epithelial ovarian, fallopian tube, and primary peritoneal carcinoma. That lets pathologists flag patients who might benefit from […]
Merck & Co., Inc. (NYSE:MRK) outlined its HIV treatment and prevention strategy at an investor event following the International AIDS Conference, highlighting Phase III results for a once-weekly oral HIV regimen and its plans for a monthly oral pre-exposure prophylaxis, or PrEP, candidate. Comp
A Mizuho healthcare analyst says merging two of pharma's biggest names could unlock a fortune, but the math only works if one brutal condition is met.
J&J's oncology business posted strong Q2 growth as Darzalex, Erleada and newer cancer drugs boosted sales and advanced its long-term ambitions.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
